Blood–brain barrier models:in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The majority of therapeutics, small molecule or biologics, developed for the CNS do not penetrate the blood-brain barrier (BBB) sufficiently to induce pharmacologically meaningful effects on CNS targets. To improve the efficiency of CNS drug discovery, several in vitro models of the BBB have been used to aid early selection of molecules with CNS exposure potential. However, correlative studies suggest relatively poor predictability of in vitro BBB models underscoring the need to combine in vitro and in vivo BBB penetration assessment into an integrated preclinical workflow. AREAS COVERED: This review gives a brief general overview of in vitro and in vivo BBB models used in the pre-clinical evaluation of CNS-targeting drugs, with particular focus on the recent progress in developing humanized models. The authors discuss the advantages, limitations, in vitro-in vivo correlation, and integration of these models into CNS drug discovery and development with the aim of improving translation. EXPERT OPINION: Often, a simplistic rationalization of the CNS drug discovery and development process overlooks or even ignores the need for an early and predictive assessment of the BBB permeability. Indeed, past failures of CNS candidates in clinical trials argue strongly that the early deployment of in vitro and in vivo models for assessing BBB permeability, mechanisms of transport and brain exposure of leads, and the co-development of BBB delivery strategies will improve translation and increase the clinical success of CNS pipelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185 · cited 4×
“In addition to the physical barrier for paracellular migration of drugs, the BBB endothelium is enriched with a battery of polarized efflux transporters, the prototypical being P-glycoprotein, which eliminates substrate-drugs from the brain [2,5].”
BackgroundInfluentialDevelopment, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452 · cited 1×
“The specialized phenotype of microvascular brain endothelial cells (BEC) is induced by the ‘brain microenvironment’ during development [6,7] and maintained by close interactions with neighboring cells [7,8].”
BackgroundQuantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells
Lippmann, E. S., Azarin, S. M., Kay, J. E., Nessler, R. A., Wilson, H. K., Al-Ahmad, A., Palecek, S. P., & Shusta, E. V. (2012) · Nature Biotechnology · doi:10.1038/nbt.2247 · Cited by 800
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · cited 2×
“The requirement for a transporter to allow biologics to enter the CNS also introduces a consideration of selective expression/abundance of the transporter in the BBB endothelium versus peripheral organs to avoid a peripheral ‘sink’ [41,72,78,82].”
BackgroundEvidence for bulk flow of brain interstitial fluid: significance for physiology and pathology
Abbott, N. J. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2003.11.006 · Cited by 786
Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study.
Butt, A. M., Jones, H. C., & Abbott, N. J. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018243 · Cited by 775 · cited 1×
“Finally, a combination of RA treatment and sequential coculture of hPSC-derived BMECs with human pericytes followed by astrocytes and neurons differentiated from neural progenitors synergistically elevated TEER levels to over 5000 W cm(2), comparable to in vivo values [52,53].”
BackgroundThe hCMEC/D3 cell line as a model of the human blood brain barrier
Weksler, B., Romero, I. A., & Couraud, P.-O. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-16 · Cited by 753 · cited 1×
“Given labor intensive isolation and characterization protocols for primary cells and their limited yields, the field has invested a significant effort in developing and characterizing immortalized BEC cell lines, including mouse [27], rat [19,28], and human [29-31], to accommodate testing of larger sets and libraries…”
BackgroundA new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728 · cited 4×
“Ample literature evidence indicates that parenchymal cells play different roles in inducing and maintaining the BBB phenotype; while, pericytes were found to induce BBB differentiation and reduce pinocytosis [12,35]; the astrocyte secretome has been considered critical Barrier cells ECM”
BackgroundMethodInfluentialPhase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697 · cited 1×
“CNS indications suffer from one of the highest clinical attrition rates in the industry [1].”
BackgroundBlood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549 · cited 1×
“Since transcellular receptor-mediated transcytosis (RMT) is the principal transport pathway used by these BBB-crossing carriers [85,86], in vitro BBB models used for this purpose should express/replicate RMT receptor enrichment and function seen in vivo.”
BackgroundLippmann, E. S., Al-Ahmad, A., Azarin, S. M., Palecek, S. P., & Shusta, E. V. (2014) · Scientific Reports · doi:10.1038/srep04160 · Cited by 508 · cited 1×
“The BBB phenotype of these stem-cell derived BEC was further enhanced by the RA [51] via inducing an earlier onset of VE-cadherin expression, higher tight junction complexity, and mRNA upregulation of multiple efflux pumps (e.”
BackgroundElectrical resistance of brain microvascular endothelium
Crone, C., & Olesen, S. P. (1982) · Brain Research · doi:10.1016/0006-8993(82)91227-6 · Cited by 491 · cited 1×
“Finally, a combination of RA treatment and sequential coculture of hPSC-derived BMECs with human pericytes followed by astrocytes and neurons differentiated from neural progenitors synergistically elevated TEER levels to over 5000 W cm(2), comparable to in vivo values [52,53].”
BackgroundNakagawa, S., Deli, M. A., Nakao, S., Honda, M., Hayashi, K., Nakaoke, R., Kataoka, Y., & Niwa, M. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9195-4 · Cited by 364
Diffusion of Macromolecules in the Brain: Implications for Drug Delivery
Wolak, D. J., & Thorne, R. G. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300495e · Cited by 299 · cited 1×
“Once within the CNS, diffusion is more limited than for small molecules [83] and target-mediated disposition more pronounced because therapeutic antibodies are usually developed to have high affinities against target epitopes.”
BackgroundRetinoic Acid Induces Blood–Brain Barrier Development
Mizee, M. R., Wooldrik, D., Lakeman, K. A. M., van het Hof, B., Drexhage, J. A. R., Geerts, D., Bugiani, M., Aronica, E., Mebius, R. E., Prat, A., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1338-12.2013 · Cited by 203 · cited 1×
“Some brain microenvironment-inducing effects on the BBB phenotype can be recapitulated pharmacologically, by targeting the BEC canonical Wnt pathway [37] or by adding retinoic acid (RA) [38].”
BackgroundAbbott, N. J. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.014 · Cited by 181 · cited 2×
“The exchange and flux of circulatory molecules, including drugs, across the BBB in vivo is determined by their molecular size and physicochemical properties, as well as by complex binding and elimination processes occurring in the circulation, peripheral organs, at the BBB and in the brain parenchyma and its fluids [4…”
Background‘Sealing off the CNS’: cellular and molecular regulation of blood–brain barriergenesis
Siegenthaler, J. A., Sohet, F., & Daneman, R. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.06.006 · Cited by 115
Cited by
Brown, J. A., Pensabene, V., Markov, D. A., Allwardt, V., Neely, M. D., Shi, M., Britt, C. M., Hoilett, O. S., Yang, Q., Brewer, B. M., et al. (2015) · Biomicrofluidics · doi:10.1063/1.4934713 · Cited by 410
Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356
Bigal, M. E., Dodick, D. W., Rapoport, A. M., Silberstein, S. D., Ma, Y., Yang, R., Loupe, P. S., Burstein, R., Newman, L. C., & Lipton, R. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00249-5 · Cited by 287
Bigal, M. E., Edvinsson, L., Rapoport, A. M., Lipton, R. B., Spierings, E. L. H., Diener, H.-C., Burstein, R., Loupe, P. S., Ma, Y., Yang, R., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00245-8 · Cited by 261
Ribecco-Lutkiewicz, M., Sodja, C., Haukenfrers, J., Haqqani, A. S., Ly, D., Zachar, P., Baumann, E., Ball, M., Huang, J., Rukhlova, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19522-8 · Cited by 148
Self-citation
Metadata
- Authors
- Stanimirovic, D. B., Bani-Yaghoub, M., Perkins, M., & Haqqani, A. S.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2014-11-12
- Volume
- 10
- Issue
- 2
- Pages
- 141-155
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2065377594
- Cited by
- 83
- References
- 18
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.